News

CARB-X News

  • 07.10.2018  |  CARB-X funds Summit Therapeutics to support development of a new class of antibiotics to treat Gonorrhoea Superbug

    CARB-X awards Summit Therapeutics $2 million in non-dilutive funding, with the possibility of up to $2.5 million more, to support the development of a new class of antibiotics to treat gonorrhoea. This project bring to 10 the number of new classes in the portfolio; 34 projects to fight superbugs

    Full Story

  • 05.22.2018  |  UK Government and Bill & Melinda Gates Foundation join CARB-X partnership in fight against superbugs

    The UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.

    Full Story

  • 05.15.2018  |  CARB-X funds MicrobeDx to support development of a transformative testing system to rapidly diagnose life-threatening infections in the urinary tract

    MicrobeDx’s system could diagnose infections and identify the bug causing it within 30 minutes, and tell doctors within three hours which antibiotic to prescribe to kill the bacteria

    Full Story

  • 05.10.2018  |  CARB-X funds Talis Biomedical to develop systems to diagnose chlamydia and gonorrhea within minutes and determine which antibiotics would kill the bacteria

    CARB-X is awarding Talis Biomedical Corporation of Menlo Park, CA, up to $4.4 million, with the possibility of up to $4.2 million more based on achievement of project milestones, to support the development of the company's molecular diagnostic system which would speed diagnosis and appropriate treatment of chlamydia and gonorrhea, including drug-resistant infections.

    Full Story

  • 05.07.2018  |  CARB-X partners with Melinta Therapeutics to accelerate the development of a new class of antibiotic to battle multiple life-threatening superbugs

    CARB-X is teaming up with Melinta Therapeutics (NASDAQ: MLNT) to support the development of a new class of antibiotic called pyrrolocytosine to treat the most serious drug-resistant bacterial infections.

    Full Story

  • 04.26.2018  |  CARB-X announces award to Achaogen to advance the development of next-generation aminoglycoside antibiotic to treat highly-resistant gram-negative pathogens

    CARB-X is funding Achaogen, Inc. (NASDAQ: AKAO) of South San Francisco, CA, to support the development of a next-generation broad-spectrum aminoglycoside antibiotic capable of overcoming resistance mechanisms and potentially treating highly-resistant pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii.

    Full Story

  • 04.20.2018  |  CARB-X funds Idorsia to accelerate the early development of a new class of antibiotic to treat deadly drug-resistant bacterial infections

    CARB-X announced today a funding agreement with Idorsia (SIX: IDIA.S) of Allschwil, Switzerland, to support the development of a new class of antibiotic, a novel dual-acting topoisomerase inhibitor, to treat patients with infections caused by drug-resistant bacteria.

    Full Story

  • 04.03.2018  |  CARB-X funds Specific Diagnostics to support the development of a rapid accurate test to diagnose life-threatening drug-resistant infections in the blood

    Specific's antibiotic susceptibility testing system promises accurate drug susceptibility and identification of superbugs within 4 hours of a positive blood sample, reducing the chance of life-threatening sepsis and other urgent complications of blood infections.

    Full Story

  • 03.22.2018  |  CARB-X funds Shionogi to develop an antibiotic to treat infections caused by the life-threatening CRE superbug

    CARB-X is funding Shionogi of Osaka, Japan, to support the development of a novel β-lactam antibiotic with potent activity against the dreaded superbug serine- and metallo-type carbapenemase-producers, including BL/BLI-resistant carbapenem-resistant Enterobacteriaceae (CRE)

    Full Story

  • 03.15.2018  |  CARB-X teams up with HelixBind to support the development of a test to diagnose life-threatening bloodstream infections linked to sepsis

    CARB-X is awarding HelixBind of Marlborough, MA, up to $1 million, with the possibility of up to $1 million more based on achievement of project milestones, to support the development of the company's RaPID/BSI diagnostic test for invasive bloodstream infections.

    Full Story

  • 03.06.2018  |  CARB-X partners with T2 Biosystems to develop tests to identify and diagnose drug-resistant bacteria direct from blood

    CARB-X is funding T2 Biosystems, Inc. of Lexington, MA (NASDAQ: TTOO) to support the development of new tests using the company's T2 Magnetic Resonance technology that would enable doctors to quickly diagnose and treat life-threatening, drug-resistant bacterial infections in whole blood.

    Full Story

  • 03.05.2018  |  CARB-X partners with MicuRx to develop a polymyxin antibiotic to treat multi-drug resistant Gram-negative superbugs including E. coli, P. aeruginosa, K. pneumoniae and A. baumannii

    CARB-X is teaming up with MicuRx Pharmaceuticals Inc. of Hayward, CA, to support the early development of its polymyxin antibiotic MRX-8 to treat the most serious multi-drug-resistant bacterial infections, including infections caused by Gram-negative pathogens E. coli, P. aeruginosa, K. pneumoniae and A. baumannii.

    Full Story

  • 03.01.2018  |  CARB-X partners with Macrolide Pharmaceuticals to develop novel macrolide antibiotics with Gram-negative activity

    CARB-X is funding Macrolide Pharmaceuticals of Watertown, MA, to support the development of a novel fully synthetic, orally available macrolide antibiotic with Gram-negative activity, with the aim of treating serious infections including drug-resistant complicated urinary tract infections (cUTI).

    Full Story

  • 02.20.2018  |  CARB-X launches its 2018 rounds of funding and invites applications

    CARB-X announced today its 2018 rounds of funding to support research into the development of antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria.

    Full Story

  • 02.15.2018  |  CARB-X teams up with Curza to develop a new class of antibiotics to treat drug-resistant Gram-negative bacteria

    CARB-X is funding Curza of Salt Lake City, UT, to support the development of a new class of antibiotics to treat a broad spectrum of life-threatening Gram-negative bacteria that are resistant to existing antibiotics.

    Full Story

  • 01.24.2018  |  New global approach and greater financial incentives needed to drive antibiotic innovation, concludes Drive-AB final study on combating the global drug resistance threat

    $1-billion market-entry reward for each new antibiotic approved, doubling research investment for groups like CARB-X, and new concerted approach needed to drive antibiotic innovation and ensure access and sustainable use

    Full Story

  • 01.23.2018  |  Carb-X Is Seeking Additional Accelerators To Expand Support For Its Growing Early Development Antibacterial Pipeline

    CARB-X is seeking to partner with up to 6 additional accelerator organizations to expand its drug development and business support for its growing pipeline of early development antibacterial research projects. Applications are welcome until March 30, 2018.

    Full Story